Amir Heshmatpour Purchases 15,000 Shares of Neonc Technologies (NASDAQ:NTHI) Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour purchased 15,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was acquired at an average cost of $3.96 per share, with a total value of $59,400.00. Following the transaction, the chief executive officer directly owned 3,148,000 shares of the company’s stock, valued at approximately $12,466,080. This represents a 0.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Neonc Technologies Trading Down 9.7%

NTHI stock opened at $2.99 on Thursday. Neonc Technologies Holdings, Inc. has a 1-year low of $2.95 and a 1-year high of $12.99. The business’s 50 day moving average is $4.01 and its 200-day moving average is $5.22.

Neonc Technologies (NASDAQ:NTHI) last posted its earnings results on Monday, August 10th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTHI. Global Retirement Partners LLC acquired a new stake in Neonc Technologies in the 2nd quarter valued at about $126,000. BlackRock Inc. acquired a new position in shares of Neonc Technologies during the second quarter worth approximately $815,000. Westmount Partners LLC lifted its position in shares of Neonc Technologies by 355.2% during the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after purchasing an additional 153,858 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of Neonc Technologies during the second quarter valued at approximately $1,017,000.

More Neonc Technologies News

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: Executives, including CEOs Amir F. Heshmatpour and Thomas C. Chen and CFO Keithly Garnett, bought shares in multiple transactions. Heshmatpour purchased a combined 87,000 shares across recent trades, while Chen bought 10,798 shares. The purchases may signal management confidence that NTHI is undervalued. NeOnc executive stock purchase announcement
• Positive Sentiment: Positive Phase 2a data for NEO100 has shifted investor focus toward the program’s next regulatory milestone and the possibility of FDA engagement. Further clinical or regulatory progress could provide a catalyst for the shares. NEO100 data and FDA article
• Positive Sentiment: NeOnc’s targeted-delivery platform and additional CNS cancer candidates, including preclinical NEO212, provide potential long-term value if the company can advance its pipeline successfully. NeOnc platform and pipeline article
• Neutral Sentiment: Analyst views are mixed: three analysts rate NTHI Buy, one rates it Hold and one rates it Sell. The reported consensus is Hold, despite price targets well above the current trading range, reflecting the uncertainty of an early-stage biotechnology company.
• Negative Sentiment: NeOnc’s latest quarterly loss of $0.58 per share was substantially worse than the expected $0.12 loss, raising concerns about cash burn and the funding needed to reach commercialization.
• Negative Sentiment: A recent roughly $15 million financing may support NEO100 development, but potential equity issuance can dilute existing shareholders. The shares have also declined sharply, remain below their 50-day and 200-day moving averages, and are near their 12-month low.

Analyst Ratings Changes

NTHI has been the topic of several analyst reports. Wall Street Zen lowered shares of Neonc Technologies from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings upgraded shares of Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. Finally, BTIG Research reaffirmed a “buy” rating and set a $15.00 price objective on shares of Neonc Technologies in a research note on Tuesday, September 8th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $16.00.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.